CA2945548C - Method of preparing cells for 3d tissue culture - Google Patents
Method of preparing cells for 3d tissue culture Download PDFInfo
- Publication number
- CA2945548C CA2945548C CA2945548A CA2945548A CA2945548C CA 2945548 C CA2945548 C CA 2945548C CA 2945548 A CA2945548 A CA 2945548A CA 2945548 A CA2945548 A CA 2945548A CA 2945548 C CA2945548 C CA 2945548C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cndot
- tissue culture
- cell
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 238000007747 plating Methods 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims description 169
- 210000003494 hepatocyte Anatomy 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 8
- 239000000017 hydrogel Substances 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001338 self-assembly Methods 0.000 claims description 6
- 231100000747 viability assay Toxicity 0.000 claims description 6
- 238000003026 viability measurement method Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 5
- 231100000041 toxicology testing Toxicity 0.000 claims description 4
- 238000009511 drug repositioning Methods 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 231100000750 In vitro toxicology Toxicity 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 85
- 210000004185 liver Anatomy 0.000 description 29
- 230000035899 viability Effects 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 238000012604 3D cell culture Methods 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 9
- 238000010257 thawing Methods 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 231100000334 hepatotoxic Toxicity 0.000 description 6
- 230000003082 hepatotoxic effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 4
- 229960000497 trovafloxacin Drugs 0.000 description 4
- 238000012605 2D cell culture Methods 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002723 toxicity assay Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 238000013335 3D tissue model Methods 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1406716.9A GB201406716D0 (en) | 2014-04-15 | 2014-04-15 | Method of preparing cells for 3D tissue culture |
| GB1406716.9 | 2014-04-15 | ||
| PCT/EP2015/058174 WO2015158777A1 (en) | 2014-04-15 | 2015-04-15 | Method of preparing cells for 3d tissue culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2945548A1 CA2945548A1 (en) | 2015-10-22 |
| CA2945548C true CA2945548C (en) | 2019-11-12 |
Family
ID=50844988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2945548A Active CA2945548C (en) | 2014-04-15 | 2015-04-15 | Method of preparing cells for 3d tissue culture |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170037364A1 (OSRAM) |
| EP (1) | EP3132023B1 (OSRAM) |
| JP (1) | JP6492106B2 (OSRAM) |
| CN (1) | CN106459895B (OSRAM) |
| AU (1) | AU2015248875B9 (OSRAM) |
| CA (1) | CA2945548C (OSRAM) |
| DK (1) | DK3132023T3 (OSRAM) |
| GB (1) | GB201406716D0 (OSRAM) |
| SG (1) | SG11201608463WA (OSRAM) |
| WO (1) | WO2015158777A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6758026B2 (ja) * | 2015-04-17 | 2020-09-23 | 株式会社日立ハイテク | 成分分析装置、薬剤成分分析装置、成分分析方法及び薬剤成分分析方法 |
| EP3397753B1 (en) * | 2015-12-30 | 2021-10-27 | FUJIFILM Cellular Dynamics, Inc. | Microtissue formation using stem cell-derived human hepatocytes |
| GB201609663D0 (en) | 2016-06-02 | 2016-07-20 | Stemtek Therapeutics Sl | Methods for producing cancer stem cell spheroids |
| EP3592842A1 (en) * | 2017-03-10 | 2020-01-15 | Merck Patent GmbH | Infected cell cultures |
| CN109294971A (zh) * | 2018-09-29 | 2019-02-01 | 西安交通大学 | 一种用于药物筛选的颈动脉分叉三维细胞培养模型及其构建方法 |
| DE102019216886A1 (de) | 2019-10-31 | 2021-05-06 | Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. | Transfer zumindest eines partikels in einer flüssigkeit von einer abgabeeinheit zu einer empfangseinheit |
| CN111471641B (zh) * | 2020-02-03 | 2021-11-05 | 东华大学 | 多片层单元水凝胶包被的仿生毛细血管网的3d打印制法 |
| CN111150885A (zh) * | 2020-03-05 | 2020-05-15 | 陕西佰傲干细胞再生医学有限公司 | 软骨微囊及其制备方法和应用 |
| US12076437B2 (en) | 2021-07-12 | 2024-09-03 | Brown University | Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue |
| WO2025073379A1 (en) | 2023-10-06 | 2025-04-10 | Insphero Ag | Device for studying interactions of biological specimen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2545100B1 (fr) * | 1983-04-29 | 1985-12-20 | Inst Nat Sante Rech Med | Procede d'obtention de cultures d'hepatocytes humains, les cultures obtenues et leurs applications biologiques et biochimiques |
| WO2003055487A1 (en) * | 2002-01-04 | 2003-07-10 | The University Of Adelaide | METHOD OF CONTROLLING DAMAGE MEDIATED BY α, β- UNSATURATED ALDEHYDES |
| EP1496978A4 (en) * | 2002-04-03 | 2006-11-29 | Artecel Sciences Inc | IMPROVEMENTS IN DIFFERENTIATED ADULT DIFFERENTIATED STEM CELLS DERIVED FROM ADIPOSE TISSUE AND USES THEREOF |
| JP2004254674A (ja) * | 2003-02-25 | 2004-09-16 | Mutsumi Takagi | 動物細胞の分化誘導培養方法 |
| KR101536613B1 (ko) * | 2004-09-24 | 2015-07-14 | 메소블라스트, 아이엔씨. | 증폭된 다능성 간엽 전구세포 자손 및 이의 용도 |
| WO2007124023A2 (en) * | 2006-04-21 | 2007-11-01 | Wake Forest University Health Sciences | Ink-jet printing of tissues |
| CN101631852A (zh) * | 2006-10-23 | 2010-01-20 | 人类起源公司 | 用胎盘细胞群治疗骨缺损的方法和组合物 |
| US10494607B2 (en) * | 2007-02-12 | 2019-12-03 | Celularity, Inc. | CD34+,CD45−placental stem cell-enriched cell populations |
| ES2749500T3 (es) * | 2008-11-19 | 2020-03-20 | Celularity Inc | Células adherentes derivadas del amnios |
| WO2010060080A1 (en) * | 2008-11-24 | 2010-05-27 | Immunotrex Corporation | Three dimensional tissue generation |
| EP2488209B1 (en) * | 2009-10-16 | 2016-09-28 | Rutgers, the State University of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
| EP2806023B1 (en) * | 2009-11-30 | 2015-09-23 | Pluristem Ltd. | Adherent cells from placenta and use of same in disease treatment |
| US20110229970A1 (en) * | 2010-03-05 | 2011-09-22 | Florida State University Research Foundation | Dual-chamber perfusion bioreactor for orthopedic tissue interfaces and methods of use |
| CN103097517A (zh) * | 2010-06-11 | 2013-05-08 | 塞拉帝思股份公司 | 用于提高多能干细胞分化成肝细胞的3维支架 |
| KR20140003473A (ko) * | 2010-12-17 | 2014-01-09 | 안트로제네시스 코포레이션 | 양막 유래 부착성 세포를 사용한, 척수 손상 및 외상성 뇌 손상의 치료 |
| US20130190210A1 (en) * | 2011-09-12 | 2013-07-25 | Organovo, Inc. | Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same |
-
2014
- 2014-04-15 GB GBGB1406716.9A patent/GB201406716D0/en not_active Ceased
-
2015
- 2015-04-15 DK DK15723435.2T patent/DK3132023T3/da active
- 2015-04-15 WO PCT/EP2015/058174 patent/WO2015158777A1/en not_active Ceased
- 2015-04-15 SG SG11201608463WA patent/SG11201608463WA/en unknown
- 2015-04-15 CA CA2945548A patent/CA2945548C/en active Active
- 2015-04-15 JP JP2016562830A patent/JP6492106B2/ja active Active
- 2015-04-15 US US15/303,455 patent/US20170037364A1/en not_active Abandoned
- 2015-04-15 AU AU2015248875A patent/AU2015248875B9/en not_active Ceased
- 2015-04-15 CN CN201580020057.0A patent/CN106459895B/zh active Active
- 2015-04-15 EP EP15723435.2A patent/EP3132023B1/en active Active
-
2023
- 2023-01-26 US US18/101,751 patent/US20230235277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20230235277A1 (en) | 2023-07-27 |
| CA2945548A1 (en) | 2015-10-22 |
| CN106459895B (zh) | 2021-06-01 |
| CN106459895A (zh) | 2017-02-22 |
| WO2015158777A1 (en) | 2015-10-22 |
| EP3132023A1 (en) | 2017-02-22 |
| AU2015248875A1 (en) | 2016-10-27 |
| JP6492106B2 (ja) | 2019-03-27 |
| JP2017511146A (ja) | 2017-04-20 |
| US20170037364A1 (en) | 2017-02-09 |
| DK3132023T3 (da) | 2021-08-09 |
| AU2015248875B9 (en) | 2019-05-23 |
| SG11201608463WA (en) | 2016-11-29 |
| AU2015248875B2 (en) | 2019-04-04 |
| EP3132023B1 (en) | 2021-06-02 |
| GB201406716D0 (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230235277A1 (en) | 3D Tissue Culture Materials and Processes for Producing Same | |
| Mohr et al. | Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models | |
| JP2024150583A (ja) | 細胞ミクロコンパートメントおよびその調製方法 | |
| Hookway et al. | Aggregate formation and suspension culture of human pluripotent stem cells and differentiated progeny | |
| CA2968655C (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
| US20180305669A1 (en) | Microtissue formation using stem cell-derived human hepatocytes | |
| Heidari Khoei et al. | Generating human blastoids modeling blastocyst-stage embryos and implantation | |
| WO2022016166A2 (en) | Differentiation of trophectoderm lineage cells from pluripotent stem cells | |
| WO2020077266A1 (en) | Compositions and methods for cell culture | |
| US11208629B2 (en) | Non-human primate induced pluripotent stem cell derived hepatocytes and uses thereof | |
| US20070148767A1 (en) | Method of forming multicellular spheroids from the cultured cells | |
| Fuegemann et al. | Differentiation of mouse embryonic stem cells into cardiomyocytes via the hanging‐drop and mass culture methods | |
| JPWO2011016485A1 (ja) | ｉＰＳ細胞から肝実質細胞への分化誘導方法 | |
| CN105695392B (zh) | 一种可提高肝细胞体外分化表型及功能的培养方法 | |
| US20230392123A1 (en) | Spheroidal self-assembled peptide hydrogels comprising cells | |
| JP6486619B2 (ja) | 薬物評価用細胞及び薬物評価方法 | |
| Raggi et al. | Generation of complex syngeneic liver organoids from induced pluripotent stem cells to model human liver pathophysiology | |
| US20200010807A1 (en) | Stepwise method for inducing cholangiocyte progenitors from hepatoblasts | |
| Gu et al. | A uterus-inspired 3D niche drives embryo development beyond implantation | |
| SIMS et al. | Examining the Effect of Cell Culture Microenvironment on Stem Cell Shape and Developmental Potential | |
| Vallverdú | Directed differentiation of human induced pluripotent stem cells to hepatic stellate cells Vallverdú, Julia; Martínez García de la Torre, Raquel A; Mannaerts, Inge; Verhulst, Stefaan; Smout, Ayla; Coll, Mar; Ariño, Silvia; Rubio-Tomás, Teresa; Aguilar-Bravo, Beatriz; Martínez-Sánchez, Celia; Blaya, Delia; Verfaillie, Catherine M; van Grunsven, Leo A; Sancho-Bru, Pau | |
| Pekkanen-Mattila | Cardiomyocyte Differentiation from Human Pluripotent Stem Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180926 |